Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG)
June 7, 2016 9:46 AM EDT
Oppenheimer maintained an Outperform rating on Alexion Pharmaceuticals (NASDAQ: ALXN), and cut the price target to $221.00 (from $228.00), following the company's announced top-line data from Phase 3 REGAIN study of eculizumab (Soliris) in refractory generalized myasthenia gravis (rGMG).
Analyst Christopher Marai commented, "Alexion announced... More
June 7, 2016 6:18 AM EDT
BMO Capital analyst, Ian Somaiya, cut his price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $160 from $168 following disappointing data from the Phase III trial of Soliris in Myasthenia Gravis (MG). Although the totality of the data suggests significant benefit, the study missed its primary endpoint... More
June 6, 2016 4:35 PM EDT
Alexion Pharma (NASDAQ: ALXN) has resumed trading and is down 8.9% after Phase 3 REGAIN study of Eculizumab did not reach statistical significance.
...
More
